Champions Oncology (CSBR) vs Heron Therapeutics (HRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Champions Oncology (CSBR) has outperformed Heron Therapeutics (HRTX) over the past year, losing 23.0% versus a loss of 73.5%. Over five years, CSBR leads with a -50.6% price change compared with -96.6% for HRTX. Champions Oncology is the larger company by market cap ($69.3 million vs $68.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | HRTX |
|---|---|---|
| Share price | $4.98 | $0.3582 |
| Market cap | $69.31M | $68.01M |
| 1-day change | +2.05% | -6.79% |
| YTD return | -27.93% | -72.45% |
| 1-year return | -23.03% | -73.47% |
| 5-year return | -50.60% | -96.62% |
| Forward P/E | 49.80 | — |
| EPS (TTM) | $-0.07 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $1.58 |
| 52-week low | $4.59 | $0.26 |
| Distance from 52-week high | -40.07% | -77.33% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1854.22% |
| Average volume | 11.33K | 2.59M |
| Shares outstanding | 13.92M | 189.85M |
| Employees | 214 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed HRTX by 50.4 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
CSBR vs HRTX FAQ
Which is bigger, Champions Oncology or Heron Therapeutics?
Champions Oncology (CSBR) is larger, with a market capitalization of $69.31M compared with $68.01M for Heron Therapeutics (HRTX).
Which stock has performed better over the past year, CSBR or HRTX?
CSBR returned -23.03% over the past 12 months, compared with -73.47% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Heron Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Champions Oncology and Biotechnology: Pharmaceutical Preparations for Heron Therapeutics.